Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

Categories Side Effects

11 through 20 of 32

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

Study : Increasing melatonin use raises concerns

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

Most relevant for: people who take or consider taking melatonin to help with sleep.

Adult use of melatonin as a sleep aid has increased even though its benefits and risks are not well understood. This study looked at trends in melatonin use over the last 19 years. (Posted 4/14/2022)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

Study : Quality of life for people with early-stage breast cancer who participated in the OlympiA clinical trial

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

Most relevant for: People with inherited mutations in BRCA1 or BRCA2 who have been diagnosed with early-stage, HER2-negative breast cancer.

The OlympiA study showed that the PARP inhibitor olaparib (Lynparza) is effective when used as maintenance therapy for people with an inherited BRCA1 or BRCA2 mutation who have early-stage breast cancer. Patient-reported outcomes from OlympiA suggest that olaparib was well tolerated and did not reduce quality of life or delay recovery from chemotherapy. (posted 2/22/22) Update: Based on OlympiA results, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who were diagnosed with early-stage HER2-negative breast cancer at high risk for recurrence. (03/11/2022). 

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Cannabis use among breast cancer patients

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People interested in using cannabis to relieve treatment side effects.

This study looked at patterns of cannabis use among breast cancer patients who are members of online health communities. Almost half of the study participants reported using cannabis to help manage treatment symptoms and side effects. The study also looked at reasons why patients used cannabis, where they obtained it and whether they perceived cannabis to be safe. While this study only looked at cannabis use among breast cancer patients it is likely results would be similar among patients diagnosed with other types of cancers. (posted 1/25/22)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Physical activity may prevent chemotherapy-related cognitive decline in women with breast cancer

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People concerned about the impact of chemotherapy

Many people experience chemo brain or chemo fog (cognitive effects) during and after chemotherapy. Researchers looked at the impact of physical activity on chemotherapy-related decline in memory, attention and information processing in women with breast cancer. This study shows that more physical activity before and during chemotherapy is linked to better information processing after chemotherapy. (Posted 1/6/22)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Update : Stronger guidance about breast implant safety

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with or considering breast implants

The FDA issued new guidance for breast implants so that all people with breast implants have the appropriate information to understand and make decisions about their healthcare. Required features include box warning, patient decision checklist, guidelines for screening for implant ruptures and patient device cards. (posted 12/14/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Human Research

Study : Bone-protecting drugs cut the risks for fractures caused by metastatic prostate cancer treatments

Relevance: Medium-High

Strength of Science: High

Research Timeline: Human Research

Most relevant for: People with metastatic castration resistant prostate cancer

Skeletal problems, especially bone fractures, are common in patients with advanced prostate cancer. To prevent these, many guidelines recommend the use of bone-protecting agents during treatment. The importance of giving a bone-protecting agent when treating patients with metastatic castration-resistant prostate cancer and bone metastases was confirmed in early results of an ongoing phase III trial. (11/5/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Guideline : ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with early-stage HER2-negative breast cancer and an inherited BRCA mutation

The American Society of Clinical Oncology (ASCO) has updated their breast cancer treatment guidelines to include treatment with the PARP inhibitor olaparib (Lynparza) for one year after completing chemotherapy, surgery and radiation (if used) to improve outcomes of people with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence. (posted 8/6/21) Update: Based on results from the OlympiA Study, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who have been diagnosed with early-stage HER2-negative breast cancer and are at high risk for recurrence. (03/11/2022)

Este artículo está disponible en español.

Read More

Relevance: High

Research Timeline: Post Approval

Guideline : Expert guidelines on COVID-19 vaccines and timing of breast screening tests

Relevance: High

Research Timeline: Post Approval

Most relevant for: People considering screening mammography after getting a COVID-19 vaccine.

COVID-19 vaccines work by helping the immune system destroy the virus. Lymph nodes are an important part of the immune system. COVID-19 vaccines may cause temporary swelling in some lymph nodes, which may look suspicious on a mammogram.  The Society for Breast Imaging and other professional organizations have released recommendations for the timing of mammograms after COVID-19 vaccines.  (3/30/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : How breast cancer patients experience hormone therapy

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Breast cancer patients taking or considering taking hormone therapy

Side effects from hormone therapy are a common reason that many men and women with hormone receptor-positive breast cancer stop treatment early. Some people never start hormone therapy. This study asked patients about their experiences with hormone (or endocrine) therapy. The results suggest that there may be ways to improve the number of patients who stick with therapy. Patients need better ways to manage hormone therapy-related side effects. (1/19/21)

Este artículo está disponible en español.

Read More

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Personal Story : Coping with chemotherapy-induced hair loss

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: People who receive chemotherapy for cancer treatment

Ovarian cancer survivor Stephanie Hess shared her personal story about how she coped with hair loss. This XRAY review also includes treatments to reduce this common side effect of chemotherapy. (9/28/20)

Read More